How many stocks are there of Mediwound?
The current number of stocks of Mediwound is 9.01 M undefined.
Mediwound Stocks 2024
Mediwound Stocks
9.01 M
Ticker
MDWD
ISIN
IL0011316309
WKN
A110TG
In 2024, Mediwound had 9.01 M outstanding stocks, a 0% change from the 9.01 M stocks in the previous year.
The Mediwound Stocks history
| YEAR | NUMBER OF STOCKS (undefined USD) |
|---|---|
| 2029e | 9.01 |
| 2028e | 9.01 |
| 2027e | 9.01 |
| 2026e | 9.01 |
| 2025e | 9.01 |
| 2024e | 9.01 |
| 2023 | 9.01 |
| 2022 | 4.99 |
| 2021 | 3.89 |
| 2020 | 3.89 |
| 2019 | 3.88 |
| 2018 | 3.87 |
| 2017 | 3.33 |
| 2016 | 3.12 |
| 2015 | 3.1 |
| 2014 | 2.85 |
| 2013 | 2.24 |
| 2012 | 2.46 |
| 2011 | 2.24 |
Mediwound shares outstanding IL0011316309 · A110TG
The number of shares was Mediwound in 2023 — This indicates how many shares 9.013 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Mediwound earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Mediwound's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Mediwound’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Mediwound's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2011 | 2.24 M Aktien |
| 2012 | 2.46 M Aktien |
| 2013 | 2.24 M Aktien |
| 2014 | 2.85 M Aktien |
| 2015 | 3.1 M Aktien |
| 2016 | 3.12 M Aktien |
| 2017 | 3.33 M Aktien |
| 2018 | 3.87 M Aktien |
| 2019 | 3.88 M Aktien |
| 2020 | 3.89 M Aktien |
| 2021 | 3.89 M Aktien |
| 2022 | 4.99 M Aktien |
| 2023 | 9.01 M Aktien |
| 2024e | 9.01 M Aktien |
| 2025e | 9.01 M Aktien |
| 2026e | 9.01 M Aktien |
| 2027e | 9.01 M Aktien |
| 2028e | 9.01 M Aktien |
| 2029e | 9.01 M Aktien |
Mediwound Aktienanalyse
What does Mediwound do?
Mediwound Ltd is an Israeli company specializing in the development and marketing of therapies for chronic and acute wounds. The company was founded in 2000 and is headquartered in Yavne, Israel. Its history began with the idea of developing an innovative treatment method for burns. The company collaborated closely with the Israeli Ministry of Defense to find a better method for wound treatment. The result was the product NexoBrid, an enzymatic debridement treatment that aims to remove dead tissue from burn wounds to enable faster healing. Mediwound's business model is to develop and market innovative drugs and therapy solutions for wounds. The company operates in several areas, including burn wounds, chronic wounds, and trauma wounds. In the burn wounds sector, Mediwound offers the product NexoBrid, which enzymatically removes dead tissue from burns and eliminates neurotoxic substances that can damage wound healing if left in the tissue for too long. NexoBrid is already approved in several countries, including the USA and European countries. In the chronic wounds sector, Mediwound offers the product EscharEx, which is used to treat chronic wounds such as pressure ulcers, diabetic foot ulcers, and venous leg ulcers. EscharEx also uses an enzymatic approach and aims to remove dead tissue to enable the body's natural healing process. There are plans to launch EscharEx in Europe in the second half of 2021. Mediwound also operates in the trauma wounds sector and received the product MWPC003 in Europe in 2020. It is a novel enzymatic debriding product that can be used in the integrated therapy of complex trauma wounds with additional topical treatment options. Through the development of innovative therapies and drugs, Mediwound has established itself as a reliable partner in wound treatment. The company continues to focus on innovation and plans to expand its product range in the future. Overall, Mediwound Ltd is a groundbreaking company in the field of wound care. The company's products and solutions contribute to faster and more effective wound healing, improving the lives of patients worldwide. Mediwound ist eines der beliebtesten Unternehmen auf Eulerpool.com.Stocks Details
Evaluating Mediwound's Shares Outstanding
Mediwound's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Year-to-Year Comparison
Tracking the changes in Mediwound’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
Impact on Investments
For investors, understanding Mediwound’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Interpreting Changes in Shares Outstanding
Variances in Mediwound’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
Frequently Asked Questions about Mediwound stock
What does Number of Shares / OutstandingShares mean?
The outstanding shares (or issued shares) of Mediwound are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
How has the number of shares of Mediwound evolved in recent years?
The number of shares of Mediwound has increased by 0% gestiegen compared to last year.
What does the number of shares mean for investors?
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
Why does the number of stocks fluctuate?
There are various factors that can lead to a change. Mediwound as a company can issue new shares, carry out stock splits or reverse splits.
Does the number of shares have an impact on the performance of Mediwound?
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
How much dividend does Mediwound pay?
Over the past 12 months, Mediwound paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mediwound is expected to pay a dividend of 0 USD.
What is the dividend yield of Mediwound?
The current dividend yield of Mediwound is .
When does Mediwound pay dividends?
Mediwound pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Mediwound?
Mediwound paid dividends every year for the past 0 years.
What is the dividend of Mediwound?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Mediwound located?
Mediwound is assigned to the 'Health' sector.
Wann musste ich die Aktien von Mediwound kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Mediwound from 9/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.
When did Mediwound pay the last dividend?
The last dividend was paid out on 9/18/2024.
What was the dividend of Mediwound in the year 2023?
In the year 2023, Mediwound distributed 0 USD as dividends.
In which currency does Mediwound pay out the dividend?
The dividends of Mediwound are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Mediwound
Our stock analysis for Mediwound Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mediwound Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
